Patents by Inventor Michelle R. Kuhne

Michelle R. Kuhne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210009718
    Abstract: Provided are FLT3L-Fc fusion proteins, polynucleotides encoding such fusion proteins, expression cassettes, vectors, cells and kits comprising such fusion proteins, and methods of using.
    Type: Application
    Filed: June 23, 2020
    Publication date: January 14, 2021
    Inventors: Alexandre Ambrogelly, Manuel Baca, Brian A. Carr, Hon Man Hamlet Chu, Magdeleine S. Hung, Manu Kanwar, Michelle R. Kuhne, Douglas S. Rehder, Matthew R. Schenauer, Nicholas S. Wilson
  • Publication number: 20200231683
    Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
    Type: Application
    Filed: October 1, 2019
    Publication date: July 23, 2020
    Inventors: MICHELLE R. KUHNE, Chin Pan, Josephine M. Cardarelli
  • Patent number: 10428151
    Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 1, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michelle R. Kuhne, Chin Pan, Josephine M. Cardarelli
  • Publication number: 20190031763
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Inventors: MICHELLE R. KUHNE, Peter Brams, Dawn M. Tanamachi, Alan J. Korman, Josephine M. Cardarelli
  • Publication number: 20140322208
    Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 30, 2014
    Inventors: Michelle R. Kuhne, Chin Pan, Josephine M. Cardarelli